We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-8.74%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.37B
AUM Growth
-$222M
Cap. Flow
+$343M
Cap. Flow %
14.48%
Top 10 Hldgs %
48.21%
Holding
122
New
26
Increased
34
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$66.1M
2
BDTX icon
Black Diamond Therapeutics
BDTX
+$51.6M
3
SDGR icon
Schrodinger
SDGR
+$33.9M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$30.5M
5
PYPL icon
PayPal
PYPL
+$26.5M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$37M
2
XNCR icon
Xencor
XNCR
+$18.9M
3
BNTX icon
BioNTech
BNTX
+$15.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11M
5
BABA icon
Alibaba
BABA
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 69.42%
2 Consumer Discretionary 14.34%
3 Miscellaneous 11.65%
4 Financials 1.8%
5 Technology 1.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
76
DELISTED
bluebird bio
BLUE
$4.6M 0.19%
7,720
– –
NBP
77
NovaBridge Biosciences American Depositary Shares
NBP
$184M
$4.55M 0.19%
+350,000
New +$4.37M
KRYS icon
78
Krystal Biotech
KRYS
$10.3B
$4.32M 0.18%
100,000
+20,000
+25% +$1.05M
SLDB icon
79
Solid Biosciences
SLDB
$933M
$4.3M 0.18%
120,000
– –
YI
80
111 Inc
YI
$31.6M
$4.3M 0.18%
65,000
– –
TRIL
81
DELISTED
Trillium Therapeutics Inc.
TRIL
$4.04M 0.17%
+1,000,000
New +$3.78M
KURA icon
82
Kura Oncology
KURA
$1.03B
$3.98M 0.17%
400,000
– –
PASG icon
83
Passage Bio
PASG
$16.1M
$3.94M 0.17%
+12,500
New +$3.91M
EPZM
84
CALL
DELISTED
Epizyme, Inc
EPZM
$3.88M 0.16%
+250,000
New +$5.37M
IMUX icon
85
Immunic
IMUX
$153M
$3.81M 0.16%
63,002
– –
APTX
86
DELISTED
Aptinyx Inc. Common Stock
APTX
$3.6M 0.15%
+1,666,666
New +$5.45M
AKBA icon
87
Akebia Therapeutics
AKBA
$267M
$3.22M 0.14%
425,000
– –
PRTA icon
88
Prothena Corp
PRTA
$458M
$3.21M 0.14%
300,000
– –
CLVS
89
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$3.18M 0.13%
500,000
-250,000
-33% -$2.01M
TCRR
90
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.1M 0.13%
400,000
– –
KLDO
91
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$3.08M 0.13%
500,500
– –
ORTX
92
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.01M 0.13%
40,000
+5,000
+14% +$576K
SYRS
93
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3M 0.13%
+50,614
New +$3.43M
AUTL
94
Autolus Therapeutics
AUTL
$516M
$3M 0.13%
500,000
– –
KDNY
95
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.74M 0.12%
200,000
– –
PRVL
96
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$2.44M 0.1%
+200,000
New +$3.18M
AXLA
97
DELISTED
Axcella Health Inc. Common Stock
AXLA
$2.05M 0.09%
24,000
+6,000
+33% +$615K
SYRE icon
98
Spyre Therapeutics
SYRE
$7.99B
$1.86M 0.08%
16,000
+4,000
+33% +$680K
PTLA
99
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.43M 0.06%
+200,000
New +$2.5M
IRWD icon
100
Ironwood Pharmaceuticals
IRWD
$689M
$1.11M 0.05%
110,532
– –
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2020 Portfolio in Review

As of Q1 2020, Artal Group held 122 positions worth $2.37B, down 8.6% from $2.59B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $343M of net new capital in Q1 2020, opening 26 new positions and adding to 34 existing holdings. Its largest new stake was uniQure: 1,150,000 shares worth $54.6M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 63% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Moderna, an estimated $37M trimmed.

  • Artal Group's largest Q1 2020 buy was uniQure: 1,150,000 shares worth $54.6M.
  • Artal Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020, an estimated $30.5M increase.
  • Artal Group's biggest Q1 2020 reduction was Moderna, cutting an estimated $37M.
  • Artal Group fully exited Xencor in Q1 2020, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 48% of its $2.37B portfolio in Q1 2020.
  • Artal Group opened 26 new positions and closed 19 in Q1 2020.
  • Artal Group's portfolio value fell 8.6% quarter-over-quarter to $2.37B.

Based on Artal Group's 13F filing for Q1 2020, filed 14 May 2020.